Prostate cancer diagnoses up 23% among young adults, Epic data shows

Advertisement

New prostate cancer diagnoses increased 12.08% and prostate-specific antigen screenings increased 52.18% between 2021 and 2024, according to data published Feb. 12 by Epic Research

Epic’s research division utilized data from Cosmos, a dataset created in collaboration with a community of Epic health systems representing more than 300 million patient records from the U.S., Canada, Saudi Arabia and Lebanon.

Men ages 35-44 and 55-64 experienced the largest increase in new cancer diagnoses between 2021 and 2024 at 22.81% and 22.85%, respectively.

Men ages 35-44 also experienced the largest increase in PSA screenings, with screening rates jumping 60.18% between 2021 and 2024.

Prostate cancer accounts for 30% of all male cancers and is the second-leading cause of cancer death for men behind lung cancer. According to a recent study, prostate cancer incidence in the U.S. increased 3.0% per year between 2014 through 2021, following almost a decade of decline.

Here are the changes in new prostate cancer diagnoses and PSA screenings between 2021 and 2024, according to Epic Research:

New cancer diagnoses per 100,000 patients
AgeQ1 2021Q4 2024Percentage change
35-445.7722.81%
45-5459.268.315.37%
55-64203.525022.85%
65-74356.7411.415.34%
75-84361.2403.611.74%
85+326.3330.81.38%
35-85+1312.61471.112.08%
PSA screenings per 100,000 patients
AgeQ1 2021Q4 2024Percentage change
35-441,175.91,883.560.18%
45-544,656.77,137.753.28%
55-646,497.39,69649.23%
65-745,736.18,725.452.11%
75-843,427.35,27553.91%
85+1,5152,296.151.56%
35-85+23,008.335,013.752.18%

At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.

Advertisement

Next Up in Oncology

Advertisement